Brief: Alto Neuroscience Announces Completion Of Enrollment In Phase 2 Proof-Of-Concept Study Of Alto-101
13/02/2026 13:46
Feb 13 (Reuters) - Alto Neuroscience Inc ANRO.N: ALTO NEUROSCIENCE ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2 PROOF-OF-CONCEPT STUDY OF ALTO-101 IN COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA Source text: ID:nBwblbtfra Further company coverage: ANRO.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alto Neuroscience
See all newsBrief: Alto Neuroscience Promotes Nick Smith To President And Chief Financial Officer
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Brief: Alto Neuroscience - Proposed Resale Of Up To 6 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
Brief: Alto Neuroscience Reports Topline Data From Phase 2 Proof-Of-Concept Study Of Alto-101 And Highlights Pipeline Advancements